The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer
Abstract
Lung cancer is the most common cancer, with dismal outcome. Treatment approaches, including cisplatin-based chemotherapy and surgery, are currently based on the clinical classification of the tumor, without genetic assessment for predicting differential chemosensitivity. BRCA1 plays a central role in DNA repair, and decreased BRCA1 mRNA expression in the human breast cancer HCC1937 cell line caused cisplatin hypersensitivity, but the relation between BRCA1 and survival in lung cancer patients has never been examined. We used real-time quantitative polymerase chain reaction to determine BRCA1 mRNA levels in 55 surgically resected tumors of non-small-cell lung cancer patients who had received neoadjuvant gemcitabine/cisplatin chemotherapy, and divided the gene expression values into quartiles. When results were correlated with outcome, two cut-offs were observed; patients with levels <0.61 had better outcome, and those >2.45 had poorer outcome. Median survival was not reached for the 15 patients in the bottom quartile, whereas for the 28 in the two middle quartiles, it was 37.8 months (95% CI, 10.6-65), and for the 12 patients in the top quartile, it was 12.7 months (95% CI, 0.28-28.8) (P=0.01). Moreover, when patients were stratified by pathologic stage, those in the bottom quartile had a decreased risk of death (HR=0.206; 95% CI, 0.05-0.83; P=0.026) compared with those in the top quartile, and those in the two middle quartiles also had a decreased risk of death (HR=0.294; 95% CI, 0.10-0.83; P=0.020) compared with those in the top quartile. BRCA1 expression is potentially an important tool for use in cancer management and should be assessed for predicting differential chemosensitivity and tailoring chemotherapy in lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Revisions in the International System for Staging Lung Cancer
Mountain, C. F. (1997) · Chest · doi:10.1378/chest.111.6.1710 · Cited by 4,565
Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., & Thun, M. J. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.1.8 · Cited by 3,984
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
Rosell, R., Gomez-Codina, J., Camps, C., Maestre, J., Padille, J., Canto, A., Mate, J. L., Li, S., Roig, J., Olazabal, A., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401203300301 · Cited by 1,261
Self-citationPromoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors
Esteller, M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.7.564 · Cited by 1,233 · cited 1×
“Aberrant cytosine methylation of the BRCA1 CpG island promoter may be a partial mechanism of BRCA1 repression in sporadic breast cancer (26,27).”
BackgroundLord, R. V., Brabender, J., Gandara, D. R., Alberola, V., Camps, C., Dómine, M., Cardenal, F., Sánchez, J. M., Gumerlock, P. H., Tarón, M., et al. (2002) · PubMed · Cited by 668
Self-citationInduction of GADD45 and JNK/SAPK-Dependent Apoptosis following Inducible Expression of BRCA1
Harkin, D. P., Bean, J. M., Miklos, D., Song, Y.-H., Truong, V. B., Englert, C., Christians, F. C., Ellisen, L. W., Maheswaran, S., Oliner, J. D., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80769-2 · Cited by 557
Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors
Taniguchi, T., Tischkowitz, M., Ameziane, N., Hodgson, S. V., Mathew, C. G., Joenje, H., Mok, S. C., & D'Andrea, A. D. (2003) · Nature Medicine · doi:10.1038/nm852 · Cited by 536
Wei, Q. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.21.1764 · Cited by 507
Specht, K., Richter, T., Müller, U., Walch, A., Werner, M., & Höfler, H. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63985-5 · Cited by 485
BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.
Quinn, J. E., Kennedy, R. D., Mullan, P. B., Gilmore, P. M., Carty, M., Johnston, P. G., & Harkin, D. P. (2003) · PubMed · Cited by 464
Furuta, T., Ueda, T., Aune, G. J., Sarasin, A. R., Kraemer, K. H., & Pommier, Y. G. (2002) · PubMed · Cited by 422
Martini, N., Kris, M. G., Flehinger, B. J., Gralla, R. J., Bains, M. S., Burt, M. E., Heelan, R., McCormack, P. M., Pisters, K. M. W., Rigas, J. R., et al. (1993) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(93)91072-u · Cited by 373
Rosell, R., Danenberg, K. D., Alberola, V., Bepler, G., Sanchez, J. J., Camps, C., Provencio, M., Isla, D., Taron, M., Diz, P., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0156 · Cited by 352
Self-citationRandomized trial of neoadjuvant therapy for lung cancer: Interim analysis
Pass, H. I., Pogrebniak, H. W., Steinberg, S. M., Mulshine, J., & Minna, J. (1992) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(92)90373-c · Cited by 331
Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier.
Tomlinson, G. E., Chen, T. T., Stastny, V., Virmani, A. K., Spillman, M. A., Tonk, V. S., Blum, J. L., Schneider, N. R., Wistuba, I. I., Shay, J. W., et al. (1998) · PubMed · Cited by 294
Husain, A., He, G., Venkatraman, E. S., & Spriggs, D. R. (1998) · PubMed · Cited by 291
Rice, J. C., Massey-Brown, K. S., & Futscher, B. W. (1998) · Oncogene · doi:10.1038/sj.onc.1202086 · Cited by 243
Page, F. L., Randrianarison-Huetz, V., Marot, D., Cabannes, J., Perricaudet, M., Feunteun, J., & Sarasin, A. R. (2000) · PubMed · Cited by 236
Potapova, O., Haghighi, A., Bost, F., Liu, C., Birrer, M. J., Gjerset, R., & Mercola, D. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14041 · Cited by 229
Abbott, D. W., Thompson, M. E., Robinson-Benion, C., Tomlinson, G., Jensen, R. A., & Holt, J. T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.26.18808 · Cited by 228
Gatzemeier, U., von Pawel, J., Gottfried, M., Velde, G. P. M. T., Mattson, K., DeMarinis, F., Harper, P., Salvati, F., Robinet, G., Lucenti, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.19.3390 · Cited by 226
Brodie, S. G., Xu, X., Qiao, W., Li, W.-M., Cao, L., & Deng, C.-X. (2001) · Oncogene · doi:10.1038/sj.onc.1204929 · Cited by 188
Rosell, R., Scagliotti, G., Danenberg, K. D., Lord, R. V., Bepler, G., Novello, S., Cooc, J., Crinò, L., Sánchez, J. J., Taron, M., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206419 · Cited by 188
Self-citationLafarge, S., Sylvain, V., Ferrara, M., & Bignon, Y.-J. (2001) · Oncogene · doi:10.1038/sj.onc.1204812 · Cited by 187
BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents
Mullan, P. B., Quinn, J. E., Gilmore, P. M., McWilliams, S., Andrews, H. N., Gervin, C., McCabe, N., McKenna, S., White, P., Song, Y., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204712 · Cited by 169
An Analysis of DNA Repair as a Determinant of Survival in Patients With Non-Small-Cell Lung Cancer
Bosken, C. H. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.14.1091 · Cited by 169
KRAFFT, A., DUNCAN, B., BIJWAARD, K., TAUBENBERGER, J., & LICHY, J. (1997) · Molecular Diagnosis · doi:10.1016/s1084-8592(97)80032-x · Cited by 158
Georgoulias, V., Ardavanis, A. S., Agelidou, A., Agelidou, M., Chandrinos, V., Tsaroucha, E., Toumbis, M., Kouroussis, C., Syrigos, K., Polyzos, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.004 · Cited by 134
Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1
Hussain, S. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg266 · Cited by 117
BRCA1 : mechanisms of inactivation and implications for management of patients
Kennedy, R. D., Quinn, J. E., Johnston, P. G., & Harkin, D. P. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11087-7 · Cited by 116
Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy.
Nie, Z.-R., Paterson, J., Alpert, L., Tsao, M., Viallet, J., & Alaoui-Jamali, M. (1995) · PubMed · Cited by 114
Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD.
Aloyz, R. S., Xu, Z., Bello, V., Bergeron, J., Han, F., Yan, Y., Malapetsa, A., Alaoui‐Jamali, M. A., Duncan, A. M. V., & Panasci, L. (2002) · PubMed · Cited by 88
Subcellular localization of the BRCA1 gene product in mitotic cells
Lotti, L. V., Ottini, L., D’Amico, C., Gradini, R., Cama, A., Belleudi, F., Frati, L., Torrisi, M. R., & Mariani‐Costantini, R. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10105 · Cited by 74
BRCA1 expression levels predict distant metastasis of sporadic breast cancers
Seery, L. T., Knowlden, J. M., Gee, J. M. W., Robertson, J. F. R., Kenny, F. S., Ellis, I. O., & Nicholson, R. I. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990621)84:3<258::aid-ijc10>3.0.co;2-h · Cited by 64
Association between Cyclooxygenase expression and colorectal adenoma characteristics.
Einspahr, J. G., Krouse, R. S., Yochim, J. M., Danenberg, P. V., Danenberg, K. D., Bhattacharyya, A. K., Martı́nez, M. E., & Alberts, D. S. (2003) · PubMed · Cited by 52
Cited by
Mechanisms of resistance to cisplatin and carboplatin
Stewart, D. J. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.02.001 · Cited by 631
Pisters, K. M. W., Evans, W. K., Azzoli, C. G., Kris, M. G., Smith, C. A., Desch, C. E., Somerfield, M. R., Brouwers, M. C., Darling, G., Ellis, P. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1226 · Cited by 363
Bellmunt, J., Paz-Ares, L., Cuello, M., Cecere, F. L., Albiol, S., Guillem, V., Gallardo, E., Carles, J., Mendez, P., de la Cruz, J. J., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl435 · Cited by 319
Self-citationRosell, R., Molina, M. A., Costa, C., Simonetti, S., Gimenez-Capitan, A., Bertran-Alamillo, J., Mayo, C., Moran, T., Mendez, P., Cardenal, F., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2158 · Cited by 304
“(20) Experimental (21, 22) and clinical (22, 23) studies, includingourownexperience, (23– 25) have also indicated a differential effect of BRCA1”
BackgroundSelf-citationTargeting DNA damage response in cancer therapy
Hosoya, N., & Miyagawa, K. (2014) · Cancer Science · doi:10.1111/cas.12366 · Cited by 294
Metadata
- Authors
- Taron, M., Rosell, R., Felip, E., Mendez, P., Souglakos, J., Ronco, M. S., Queralt, C., Majo, J., Sanchez, J. M., Sanchez, J. J., & Maestre, J.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-08-18
- Volume
- 13
- Issue
- 20
- Pages
- 2443-2449
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2124392685
- Cited by
- 307
- References
- 37
- FWCI
- 7.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.